Key Takeaways
- Tenet Healthcare shares skyrocketed 23% following Q2 adjusted EPS of $6.12, demolishing the analyst consensus of $4.26
- The company elevated its annual EPS forecast to $20.30ā$21.69, a significant increase from the previous $16.38ā$18.68 range
- HCA Healthcare experienced a modest 3.7% increase after confirming previously disclosed Q2 figures
- HCA reduced its annual EPS projection to $28.70ā$30.50, down from the earlier $29.10ā$31.50 estimate
- Barclays upgraded its Tenet price objective to $271 from $240, reaffirming an Overweight rating
Tenet Healthcare (THC) shares exploded 23% higher on Friday, positioning the stock for its most significant one-day advance since February. The impressive rally followed the healthcare provider’s announcement of second-quarter results that significantly exceeded Wall Street projections and a substantial upgrade to its annual forecast.
Tenet Healthcare Corporation, THC
The Dallas-based company delivered Q2 adjusted earnings of $6.12 per share, substantially surpassing the analyst consensus estimate of $4.26. Operating revenue increased 6.8% year-over-year to $5.63 billion, exceeding the anticipated $5.43 billion.
Management also elevated its full-year adjusted EPS outlook to a range of $20.30 to $21.69, representing a meaningful increase from the previous guidance of $16.38 to $18.68. The company’s annual net operating revenue forecast was similarly raised to $21.9 billionā$22.5 billion, compared to the earlier range of $21.5 billionā$22.3 billion.
The midpoint of these updated ranges substantially exceeds analyst projections ā $17.94 per share for earnings and $21.97 billion for revenue.
Contrasting Performance at HCA Healthcare
HCA Healthcare also released earnings on Friday, though market reaction proved considerably more subdued. HCA shares advanced 3.7%, a fraction of Tenet’s explosive gains.
The disparity largely stems from disclosure timing. HCA had pre-released its Q2 results on July 14, leaving little room for surprise when the official report arrived Friday.
HCA delivered Q2 adjusted EPS of $7.59, marginally exceeding the $7.56 estimate. Revenue jumped 9% to $20.23 billion, surpassing the $19.76 billion consensus forecast.
Nevertheless, a $400 million net boost from Medicaid supplemental payments substantially influenced results. Stripped of that windfall, the underlying performance painted a more complex picture.
HCA highlighted an uptick in uninsured patient volumes, partially attributed to increased loss of exchange-based insurance coverage throughout the quarter. Management calculated this dynamic reduced pre-tax income by approximately $400 million.
HCA Lowers Annual Outlook
HCA trimmed its full-year EPS guidance to $28.70ā$30.50, retreating from the prior $29.10ā$31.50 range. The Nashville-based operator also narrowed its revenue outlook to $77 billionā$79.5 billion, versus the previous $76.5 billionā$80 billion projection.
The S&P 500 declined modestly on Friday, amplifying the significance of Tenet’s 23% surge relative to broader market performance.
Barclays reacted by elevating its Tenet price target to $271 from $240, maintaining an Overweight recommendation. Analysts stated Tenet’s Q2 execution “stands out and reinforces the case for a premium valuation,” especially considering guidance reductions from competing hospital operators.
Tenet’s ambulatory surgery center platform has emerged as a crucial competitive advantage. While both organizations operate hospitals and outpatient facilities nationwide, Tenet maintains greater exposure to its surgery center segment, which has consistently delivered strong margin performance.
Barclays’ revised $271 price objective implies additional upside potential from Friday’s elevated trading levels following the post-earnings surge.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
